Loading…
Loading…
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the first quarter ended June 28, 2026, before markets open on Thursday August 06, 2026. At 8:30 a.m. Eastern on August 06, 2026, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/766230709 an.
[url="]Interactive Brokers[/url] (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea
ATS, BXBLY and SKY have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2026.
Investors need to pay close attention to ATS stock based on the movements in the options market lately.
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. (NASDAQ: FUSE), a leading provider of enterprise AI products and services, today announced expanded enterprise access to its Agentic AI for Talent Acquisition platform through new connectivity with more than 30 enterprise applicant tracking systems (ATS), enabling Fusemachines Agents to work directly within the systems organizations already use to manage talent and hiring. This expanded connectivity represents the first in a broader series of planned platform enhancements designed to bring AI-powered recruiting capabilities closer to the workflows, data, and systems recruiters rely on every day.
Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses. Based on the modeling, nerandomilast consistently increased median survival in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).1,2 Modeling predicts meaningful extensions in survival with nerandomilast, including a multi-year increase in median survival when used as monotherapy, and additional gains when added to standard treatment.1,2 Ingelheim, Germany - Long-term survival modeling of Boehringer Ingelheim's oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis (IPF) and up to 3.3 years in adults with progressive pulmonary fibrosis (PPF), compared with no therapy.1,2 These findings are based on data from the Phase III FIBRONEER™ trials and were recently presented at the ATS and EULAR 2026 international congresses.
ATS, BFC and CMC have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2026.
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Anne Cybulski, Interim Chief Financial Officer, will participate in the Stifel Summer Solstice Conference in Muskoka, ON on June 16, 2026. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Stifel representative or docampo@atsautomation.com. About ATS Corporation ATS Corporation is an industry-leading automation s.
SEC filings for ATS aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.